Neumora Therapeutics (NMRA) Cash & Equivalents (2022 - 2026)

Neumora Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $147.1 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 15.93% year-over-year to $147.1 million in Q1 2026; TTM through Mar 2026 was $147.1 million, a 15.93% increase from a year earlier, with the FY2025 full-year figure at $182.5 million, up 28.41% from the prior year.
• Cash & Equivalents declined to $147.1 million in Q1 2026 per NMRA's latest filing, from $182.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $412.3 million in Q3 2023 and bottomed at $124.5 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $182.9 million (2024), against an average of $210.4 million.
• Across the five-year window, Cash & Equivalents jumped 63.27% in 2023 and tumbled 62.0% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $240.9 million in 2022, then surged by 55.24% to $374.0 million in 2023, then tumbled by 62.0% to $142.1 million in 2024, then climbed by 28.41% to $182.5 million in 2025, then decreased by 19.43% to $147.1 million in 2026.
• Per Business Quant, the three latest NMRA Cash & Equivalents figures stand at $147.1 million (Q1 2026), $182.5 million (Q4 2025), and $129.1 million (Q3 2025).